Original ResearchClinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database
Introduction
Optimal management of metastatic castration-resistant prostate cancer (mCRPC) is still debated. Since docetaxel (DOC) approval in 2004 as first therapy able to extend overall survival (OS) in mCRPC [1], five other therapies (sipuleucel-T, cabazitaxel [CAB], abiraterone acetate [AA], enzalutamide [ENZA] and radium 223) have subsequently demonstrated an OS benefit in phase III clinical trials and were approved in this setting [2]. These phase III trials have been all conducted in parallel, with different inclusion and exclusion criteria (asymptomatic chemonaïve patients in some trials, no visceral metastases in others…) and different comparators (androgen deprivation therapy [ADT] ± prednisone with novel hormonal agents, sipuleucel-T and radium 223; mitoxantrone plus prednisone with chemotherapy or placebo).
The longest median OS in first-line mCRPC (median 34 months) has been observed in COU-AA-302 and PREVAIL phase III trials, which compared AA and ENZA in chemonaïve asymptomatic or mildly symptomatic mCRPC patients versus ADT alone [3,4]. In contrast, median OS with chemotherapy in first-line mCRPC was much shorter [1,5,6], but these trials included patients with more aggressive features, namely pain, which is a well-known poor prognostic factor [7,8]. Despite the lack of head-to-head comparisons, these novel androgen receptor-targeted therapies (ARTs) are recommended as first-line treatment by several international guidelines [2,9] and consensus conferences [10,11] for asymptomatic M1 patients until radiologic or symptomatic progression is observed, whereas chemotherapy is recommended for symptomatic patients or high-grade diseases. Of note, the NCCN guidelines recommend the use of ART solely for more severe M1 CRPC [12]. This discrepancy in recommendations highlights the need for an evidence-based and clinically driven definition of treatment sequences in mCRPC.
To identify prognostic factors, Armstrong et al. performed a multivariate analysis based on TAX327 data in mCRPC patients receiving DOC and identified several pre-treatment characteristics that could predict survival after chemotherapy [13,14]. These factors included types of disease progression, namely prostate-specific antigen (PSA) progression, bone scan progression and clinically measurable progression. In order to further validate these prognostic factors, additional analyses were carried out in patients enrolled in clinical trials, mainly in the post-DOC setting, taking into account only one line of treatment [[15], [16], [17], [18]]. In this context, we decided to conduct a post-hoc analysis of the CATS international registry [19] to evaluate the impact of progression type (PSA, radiological and clinical) at initiation of each LET on outcomes and treatment response in mCRPC. The CATS multicentre registry was designed to retrospectively collect medical data of a large cohort of consecutive mCRPC patients in a real-life setting. In addition, data were collected over three successive LETs (ART, DOC and CABA), in any order.
Section snippets
Data collection
Data were retrospectively collected from 669 consecutive patients with mCRPC treated with three consecutive LET (DOC→CABA→ART [DCA], n = 158, DOC→AA→CABA [DAC] n = 458, ART→DOC→CABA [ADC], n = 55), between November 2012 and October 2016, as previously published [19]. Confidentiality approval was obtained from the Commission Nationale de l’Informatique et des Libertés (CNIL), and the study was approved by the relevant ethics committees. All included patients were informed of this
Patient characteristics at initiation of first-LET
Among the 669 mCRPC patients included in the CATS study, type of progression was documented at initiation of first-, second- and third-LET in 661, 630 and 617 patients, respectively. Type of progression at initiation of each LET is provided in Fig. 1. Clinical progression was the most common progression type whatever the therapy line and its prevalence increased progressively with the number of lines (43.1%, 55.2% and 67.9% at first-, second- and third-LET initiation, respectively). Conversely,
Discussion
This retrospective analysis of 661 mCRPC patients treated by three LETs (DOC, CABA and one ART) provides strong evidence that clinical progression at initiation of each LET is associated with worse treatment outcomes. First, compared with patients with PSA progression only, patients with a clinical progression had a shorter OS whatever the line of treatment (9.7-month difference in first line; around 7-month difference in second- and third line) and a shorter PFS. In addition, the percentage of
Funding
This work was supported by the ARTIC association.
Conflict of interest statement
Nicolas Delanoy has received travel expenses for participation in medical meetings from Sanofi. Eleni Efstathiou has participated in studies and advisory boards for and received honoraria from Sanofi, Jannsen and Astellas and has participated in advisory boards for Tolmar, Takeda, Bayer and Tracon. Umberto Basso has received speaker fees from Bristol Meyer Squibb, Pfizer, Novartis, Pierre-Fabre and Sanofi and has participated in advisory boards for Janssen, Pfizer and Novartis. Alison Birtle
References (26)
- et al.
VENICE investigators. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
Lancet Oncol
(2013) - et al.
The phase 3 COU-AA-302 study of abiraterone acetate plus prednisone in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: stratified analysis based on pain, prostate-specific antigen, and Gleason score
Eur Urol
(2018) - et al.
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel
Eur J Cancer
(2014) - et al.
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer
Eur Urol
(2012) - et al.
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
Ann Oncol
(2016 Mar) - et al.
Sequencing of taxanes and new androgen-targeted therapies in metastatic castration-resistant prostate cancer: results of the International multicentre retrospective CATS database
Eur Urol Oncol
(2018) - et al.
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Lancet Oncol
(2015) - et al.
TAX 327 investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
N Engl J Med
(2004) - (2019)
- et al.
Abiraterone in metastatic prostate cancer without previous chemotherapy
N Engl J Med
(2013)
Enzalutamide in metastatic prostate cancer before chemotherapy
N Engl J Med
Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA
J Clin Oncol
What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
BJU Int
Cited by (6)
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study
2020, The Lancet OncologyCitation Excerpt :In the CARD study, most patients had pain progression at randomisation. Similar findings were reported in a large retrospective registry of 661 patients with metastatic castration-resistant prostate cancer treated in clinical practice.29 This situation possibly reflects recommendations of international guidelines and consensus conferences to continue androgen signalling-targeted inhibitors until unequivocal signs of progression (ie, imaging-based or clinical progression) before switching therapy.24,25
Advances in novel hormonal agents for metastatic prostate cancer
2021, Chinese Journal of UrologyDocetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study
2020, Investigative and Clinical Urology